Health care professionals who treat patients with cold agglutinin disease, a rare autoimmune hemolytic anemia, comment on symptoms that make the condition difficult to diagnose and remark on the ...

A new review maps how a clonal B-cell disorder and complement-driven hemolysis define cold agglutinin disease, why steroids ...

Cold agglutinin disease (CAD) is a rare form of autoimmune hemolytic anemia — a condition in which you have inadequate red blood cells due to premature destruction of those cells by your own immune ...

Cold agglutinin disease is a condition that causes low red blood cell (RBC) counts. Symptoms can include fatigue, weakness, or shortness of breath. Cold agglutinin disease is a type of autoimmune ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Mihir Raval, MD, MPH, comments on the difference between cold agglutinin disease and other autoimmune hemolytic anemias. Neil Minkoff, MD: Now, you had mentioned that there are other autoimmune ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Please provide your email address to receive an email when new articles are posted on . Research presented at ASH Annual Meeting and Exposition provided an exciting update on many of the ...

3D rendering Microscopic illustration of red blood cell background Researchers sought to determine whether sutimlimab would be safe and effective in treating patients with cold agglutinin disease.

PARIS – November 14, 2020 - The U.S. Food and Drug Administration issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for sutimlimab, an investigational ...

Enjaymo is the first-and-only approved therapeutic option approved for hemolytic anemia in adult patients with cold agglutinin disease Enjaymo is currently the only approved treatment for CAD and is a ...

The European Commission (EC) has granted marketing authorization for Enjaymo ® (sutimlimab) for the treatment of hemolytic anemia in adult patients with cold agglutinin disease (CAD), a rare, serious, ...